切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2019, Vol. 13 ›› Issue (02) : 109 -113. doi: 10.3877/cma.j.issn.1674-3903.2019.02.006

所属专题: 文献

论著

再次肾移植受者和移植肾长期预后影响因素分析
林锦雯1, 陈江华1,()   
  1. 1. 310003 杭州,浙江大学医学院附属第一医院肾脏病中心
  • 收稿日期:2018-08-08 出版日期:2019-05-25
  • 通信作者: 陈江华
  • 基金资助:
    国家自然科学基金(81370851)

Risk factors of kidney re-transplantation recipients and graft survival during the long-term follow-up

Jinwen Lin1, Jianghua Chen1,()   

  1. 1. Kidney Disease Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China
  • Received:2018-08-08 Published:2019-05-25
  • Corresponding author: Jianghua Chen
  • About author:
    Corresponding author: Chen Jianghua, Email:
引用本文:

林锦雯, 陈江华. 再次肾移植受者和移植肾长期预后影响因素分析[J/OL]. 中华移植杂志(电子版), 2019, 13(02): 109-113.

Jinwen Lin, Jianghua Chen. Risk factors of kidney re-transplantation recipients and graft survival during the long-term follow-up[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(02): 109-113.

目的

探究再次肾移植受者和移植肾存活情况及长期预后影响因素。

方法

回顾性分析1991年1月1日至2017年12月31日于浙江大学医学院附属第一医院肾脏病中心接受肾移植受者临床资料。共纳入再次肾移植受者37例,首次肾移植受者5 374例。根据再次肾移植受者移植肾存活时间长短,将其分为长期存活组(19例,>5年)和短期存活组(18例,≤5年)。采用成组t检验比较长期和短期存活组供受者年龄、首次与再次肾移植间隔时间、HLA错配数和再次移植供肾冷/热缺血时间。采用卡方检验比较长期和短期存活组受者性别、再次移植供肾类型、再次移植前后群体反应性抗体阳性比例、首次移植失功移植肾切除比例、再次移植前免疫诱导比例及再次移植后移植肾功能延迟恢复(DGF)和急性排斥反应发生比例。采用Kaplan-Meier法分析再次和首次肾移植受者/移植肾1、5和10年存活率。采用Cox比例风险模型分析影响再次肾移植术后移植肾长期存活影响因素。P<0.05为差异有统计学意义。

结果

截至2018年3月1日,37例再次肾移植受者中位随访时间为152个月(11~323个月),2例死亡,18例发生移植肾失功,17例移植肾功能稳定。5 374例首次肾移植受者中位随访时间为108.9个月(0.1~350.0个月),459例死亡,1 343例发生移植肾失功。再次移植组受者/移植肾1、5和10年存活率分别为86%/81%、86%/62%和82%/36%,首次移植组受者/移植肾1、5和10年存活率分别为99%/98%、93%/89%和88%/80%。再次移植组移植肾1、5和10年存活率均低于首次移植组(χ2=60.816、25.110和43.900,P均<0.05);再次移植组受者1年存活率低于首次移植组,差异有统计学意义(χ2=40.409,P<0.05)。长期和短期存活组受者再次移植后移植肾DGF和急性排斥反应发生比例差异均有统计学意义(χ2=4.039和4.748,P均<0.05)。Cox回归分析结果示DGF和急性排斥反应是影响再次肾移植受者移植肾长期存活的独立危险因素,差异有统计学意义(RR=4.317和4.571,P均<0.05)。

结论

再次肾移植受者移植肾存活率低于首次肾移植受者,DGF和急性排斥反应是影响再次移植受者移植肾存活的独立危险因素。

Objective

To investigate the risk factors of kidney re-transplantation recipients and graft survival during the long-term follow-up.

Methods

The clinical data of kidney transplant donors and recipients performed at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University from January 1, 1991 to December 31, 2017 were retrospectively analyzed. A total of 5 374 cases of first kidney transplantation and 37 cases of re-transplantation were included. In addition, the recipients of re-transplantation were divided into long-term survival group (19 cases, >5 years) and short-term survival group (18 cases, ≤5 years). The age of donor and recipient, the interval between first and second kidney transplantation, HLA mismatch and cold/warm ischemia time of donor and recipient in long-term and short-term survival groups were compared by group t test. Chi-square test was used to compare the gender of recipients, type of donor kidney, rate of positive panel reactive antibodies before and after re-transplantation, initial graft nephrectomy, immune induction before re-transplantation, delayed graft function (DGF) and acute rejection in two groups. The 1, 5 and 10-year patient/graft survival rates were calculated by Kaplan-Meier method. The Cox proportional hazard model was used to analyze the possible risk factors on long-term survival of transplanted kidney. P<0.05 was statistically significant.

Results

As of March 1, 2018, the median follow-up time of re-transplantation group was 152 months (11-323 months), 2 recipients died, 18 reipients suffered from renal allograft dysfunction and 17 patients had stable renal transplant function. The median follow-up time of the first transplantation group was 108.9 months (0.1-350.0 months). 459 cases died and 1 343 cases suffered from renal transplant failure. The 1, 5 and 10-year recipient/graft survival rates in the re-transplantation group were 86%/81%, 86%/62% and 82%/36%, and the 1, 5 and 10-year recipient/graft survival rates in the first transplantation group were 99%/98%, 93%/89% and 88%/80%. The 1, 5 and 10-year recipients survival rates of re-transplantation group were lower than those in the first transplantation group (χ2= 60.816, 25.110 and 43.900, P<0.05), and the 1-year recipients survival rate in the re-transplantation group was lower than the first transplantation group (χ2= 40.409, P<0.05). Univariate analysis showed that there were significant differences in DGF and acute rejection rates between long-term and short-term survival groups (χ2=4.039 and 4.748, P<0.05). Cox regression analysis showed that DGF and acute rejection were independent risk factors for long-term survival of transplanted kidneys in re-transplanted recipients (RR=4.317 and 4.571, P<0.05).

Conclusions

The survival rate of re-transplant recipients is lower than that of the first renal transplant recipients. DGF and acute rejection are independent risk factors affecting the survival of re-transplant recipients.

图1 37例再次肾移植受者/移植肾生存曲线
表1 再次肾移植受者移植肾长期存活影响因素分析
表2 再次肾移植受者移植肾长期存活影响因素Cox比例风险模型分析结果
1
Ojo A, Wolfe RA, Agodoa LY, et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System[J]. Transplantation, 1998, 66(12): 1651-1659.
2
MarcenR, PascualJ, TatoAM, et al. Renal transplant recipient outcome after losing the first graft[J]. Transplant Proc, 2003, 35(5): 1679-1681.
3
Coupel S, Giral-Classe M, Karam G, et al. Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months[J]. Kidney Int, 2003, 64(2): 674-680.
4
Rigden S, Mehls O, Gellert R. Factors influencing second renal allograft survival. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant AssociationJ]. Nephrol Dial Transplant, 1999, 14(3): 566-569.
5
Pour-Reza-Gholi F, Nafar M, Saeedinia A, et al. Kidney retransplantation in comparison with first kidney transplantation[J]. Transplant Proc, 2005, 37(7): 2962-2964.
6
Yagmurdur MC, Emiroglu R, Ayvaz I, et al. The effect of graft nephrectomy on long-term graft function and survival in kidney retransplantation[J]. Transplant Proc, 2005, 37(7): 2957-2961.
7
Pour-Reza-Gholi F, Nafar M, Saeedinia A, et al. Kidney retransplantation in comparison with first kidney transplantation[J]. Transplant Proc, 2005, 37(7): 2962-2964.
8
Jedrzejko K, Kieszek R, Kwapisz M, et al. Comparison of kidney transplantation results from the same deceased donor between patients with the first transplantation and retransplanted patients[J]. Transplant Proc, 2018, 50(6): 1726-1729.
9
Ingsathit A, Kantachuvesiri S, Rattanasiri S, et al. Long-term outcome of kidney retransplantation in comparison with first kidney transplantation: a report from the Thai Transplantation Registry[J]. Transplant Proc, 2013, 45(4): 1427-1430.
10
Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: Current challenges in rejection classification and prospects for adopting molecular pathology[J]. Am J Transplant, 2017, 17(1): 28-41.
11
Arnol M, Prather JC, Mittalhenkle A, et al. Long-term kidney regraft survival from deceased donors: risk factors and outcomes in a single center[J]. Transplantation, 2008, 86(8): 1084-1089.
12
韩澍,朱有华,王立明. 影响再次肾移植临床效果的主要因素[J]. 临床泌尿外科杂志,2008, 23(1): 4-6.
13
El-Agroudy AE, Wafa EW, Bakr MA, et al. Living-donor kidney retransplantation: risk factors and outcome[J]. BJU Int, 2004, 94(3): 369-373.
14
Gjertson DW. A multi-factor analysis of kidney regraft outcomes[J]. Clin Transpl, 2002, 13(2): 335-349.
15
Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence[J]. Am J Transplant, 2012, 12(2): 388-399.
16
Lim WH, Chapman JR, Wong G. Peak panel reactive antibody, cancer, graft, and patient outcomes in kidney transplant recipients[J]. Transplantation, 2015, 99(5): 1043-1050.
17
Howard RJ, Scornik J, Fennell R, et al. Results of kidney retransplantation[J]. Arch Surg, 1984, 119(7): 796-799.
18
Singh N, Diamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flowcytometry are associated with inferior kidney transplant outcomes[J]. Transplantation, 2010, 90(10): 1079-1084.
19
张勇,靳风烁,李黔生,等. 再次肾移植的临床特点及治疗体会[J]. 第三军医大学学报,2008, 30 (12): 1200-1202.
20
Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes[J]. Am J Transplant, 2009, 9(3): 536-542.
21
Paramesh AS, Zhang R, Baber J, et al. The effect of HLA mismatch on highly sensitized renal allograft recipients[J]. Clin Transplant, 2010, 24(6): E247-E252.
22
贾保祥,唐雅望,马威然,等. HLA配型和PRA对移植肾功能的影响研究[J]. 国际检验医学杂志,2011, 32(16): 1802-1804.
23
Djamali A, Muth BL, Ellis TM, et al. Banff 2011 Meeting Report: New concepts in antibody-mediated rejection[J]. Kidney Int, 2013, 3(6): 1185-1192.
24
Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch[J]. Am J Transplant, 2013, 13(1): 76-85.
25
Djamali A, Muth BL, Ellis TM, et al. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients[J]. Am J Transplant, 2012, 12(3): 563-570.
26
Viglietti D, Loupy A, Vernerey D, et al. Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss[J]. J Am Soc Nephrol, 2017, 28(2): 702-715.
27
Fernandez-Fresnedo G, Pastor JM, Lopez-Hoyos M, et al. Relationship of donor-specific class-Ⅰ anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival[J]. Nephrol Dial Transplant, 2003, 18(5): 990-995.
[1] 中华医学会器官移植学分会. 遗体捐献肾脏获取手术技术操作指南[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 257-265.
[2] 邹永康, 石雍, 徐贤刚, 张帅民, 刘衍, 杨生鹏, 叶啟发, 陈根, 张毅. 肾移植术后手术切口米根霉感染伴菌血症一例并文献复习[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 289-292.
[3] 吕玥彤, 靳梦圆, 周大为, 叶啟发. 机器人辅助下肾移植的临床进展与争议[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 242-246.
[4] 尚丽红, 王志华, 张文艳, 朱琳茹, 周华. 内皮粘蛋白抗体与肾移植术后抗体介导排斥反应和移植肾预后的研究[J/OL]. 中华移植杂志(电子版), 2024, 18(03): 165-170.
[5] 吕军好, 林锦雯, 张心怡, 陈江华. 细胞外囊泡在肾移植诊断和治疗中的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(03): 186-192.
[6] 陆婷, 陈浩, 王雪静, 谭若芸, 彭宇竹. 肾移植术后一年发生代谢综合征的危险因素分析[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 98-103.
[7] 郭明星, 徐烨, 徐菀佚, 赵莹, 刘冉佳, 潘晨, 崔向丽. 2017—2022年中国105家医院肾移植术后门诊受者免疫抑制剂用药分析[J/OL]. 中华移植杂志(电子版), 2024, 18(02): 104-109.
[8] 陆婷, 姜巧玲, 孙黎, 王雪静. 加速康复外科在肾移植围手术期应用的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 55-59.
[9] 赵丽, 蔡瑞明, 赵纪强, 林民专, 陈志勇, 彭娟. 肾移植术后新发泌尿系统恶性肿瘤二例并文献复习[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 35-39.
[10] 吴小山, 任桂灵, 朱杰东, 史天陆, 马葵芬. 肾移植受者围手术期霉酚酸暴露量及不良反应分析[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 17-21.
[11] 张心怡, 吕军好, 陈大进. 2023年肾移植领域研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(01): 7-11.
[12] 刘路浩, 张鹏, 陈荣鑫, 郭予和, 尹威, 徐璐, 李光辉, 方佳丽, 马俊杰, 陈正. 奈玛特韦/利托那韦治疗肾移植术后重型新型冠状病毒肺炎的临床效果分析[J/OL]. 中华移植杂志(电子版), 2023, 17(06): 349-353.
[13] 李晓宇, 许昕, 谌诚, 张萌, 韩文科, 林健. 肾移植受者新型冠状病毒感染合并肺炎支原体感染临床特点及诊疗分析[J/OL]. 中华移植杂志(电子版), 2023, 17(06): 354-357.
[14] 冯军, 艾麦提·牙森, 梁润斌, 廖志洪, 赵超尘, 谢嘉奋, 朱灿华, 罗燕君, 汪国营. 肝癌肝移植术前应用PD-1抑制剂后发生急性排斥反应一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 88-92.
[15] 张秋玥, 程羽, 牛雨田, 唐茂芝, 张克勤, 张懿, 郭亚楠, 涂增. 肾移植与人体微生态的相关性研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(02): 207-213.
阅读次数
全文


摘要